A Double-Blind, Placebo Controlled, Dose Ranging Study to Evaluate the Safety and Biological Efficacy of the Lipid-DNA Complex GR213487B in the Nasal Epithelium of Adult Patients with Cystic Fibrosis. Glaxo Wellcome Research and Development Ltd., London, England
- 20 January 1998
- journal article
- clinical trial
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 9 (2), 249-269
- https://doi.org/10.1089/hum.1998.9.2-249
Abstract
GTAB1001: A Double-Blind, Placebo Controlled, Dose Ranging Study to Evaluate the Safety and Biological Efficacy of the Lipid-DNA Complex GR213487B in the Nasal Epithelium of Adult Patients with Cystic Fibrosis.Keywords
This publication has 10 references indexed in Scilit:
- Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosisNature Genetics, 1994
- Adenovirus mediated expression of therapeutic plasma levels of human factor IX in miceNature Genetics, 1993
- Non–invasive liposome–mediated gene delivery can correct the ion transport defect in cystic fibrosis mutant miceNature Genetics, 1993
- Aerosol gene delivery in vivo.Proceedings of the National Academy of Sciences, 1992
- Nebulization of Liposomes. III. The Effects of Operating Conditions and Local EnvironmentPharmaceutical Research, 1992
- Acute Effects of Liposome Aerosol Inhalation on Pulmonary Function in Healthy Human VolunteersChest, 1991
- Expression of cystic fibrosis transmembrane conductance regulator corrects defective chloride channel regulation in cystic fibrosis airway epithelial cellsNature, 1990
- Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNAScience, 1989
- Electrolyte transport by airway epitheliaPhysiological Reviews, 1987
- Abnormal Ion Permeation Through Cystic Fibrosis Respiratory EpitheliumScience, 1983